Compounded GLP-1 Marketing: What Changed and What It Means for Your Ads

Compounded GLP-1 medications became a major part of the weight-loss telehealth market largely because of FDA-declared shortages of the branded products. As those shortages have resolved in various forms over time, the regulatory ground compounded GLP-1 marketing stands on has shifted with them, and clinics that built campaigns around the shortage-era rules need to check whether those rules still apply.

Why Compounding Was Allowed During the Shortage

Federal law allows compounding pharmacies to produce a version of a drug that's in FDA-declared shortage, under specific conditions, without going through the full drug approval process the branded product underwent. This is the legal basis that let compounded semaglutide and tirzepatide become widely available. That basis is tied specifically to the shortage designation, not a general right to compound any approved drug indefinitely.

What Changes When the FDA Ends a Shortage Designation

Once the FDA determines a shortage has resolved, the broad compounding allowance tied to that shortage generally ends, though compounding can still continue under narrower exceptions, such as personalized formulations for a specific patient's documented clinical need. Marketing built around "compounded is a lower-cost alternative available to anyone" needs to be reevaluated any time a shortage status changes, since the underlying legal basis for the offer may no longer apply the same way.

Marketing Claims That Need Reassessment as Rules Change

Claims implying compounded GLP-1 products are equivalent to the branded version, that they're broadly available regardless of shortage status, or that they carry FDA approval in the same sense the branded product does, all need regular reassessment against the current regulatory status, not a one-time compliance check when the campaign first launched.

Building a Process for a Regulatory Landscape That Keeps Moving

Clinics marketing compounded GLP-1 products need a recurring compliance check, not a one-time review, tied to FDA shortage status updates and any related enforcement guidance. Treating this as a static, finished piece of content is one of the more common ways clinics end up marketing an offer that's no longer legally supportable the way it once was.

Tridigiam builds a recurring compliance check into compounded GLP-1 marketing programs specifically because this regulatory ground keeps shifting. We're not a legal or regulatory compliance firm, and your specific offer needs review from your own counsel and pharmacy partners. For the broader picture on telehealth marketing, see our Telehealth & GLP-1 Marketing guide.

Frequently asked questions

Is compounded semaglutide still legal to market once the shortage ends?

It depends on the current shortage designation and whether the specific compounding falls under a narrower exception, like a personalized formulation for documented clinical need. This isn't a fixed answer, it changes as FDA shortage status changes.

Can marketing say compounded GLP-1 is equivalent to the branded drug?

This is a higher-risk claim, compounded products aren't FDA-approved in the same sense as the branded product, and implying equivalence needs careful legal review before it's used in marketing.

How often should compounded GLP-1 marketing be reviewed for compliance?

On a recurring basis tied to FDA shortage status and enforcement guidance updates, not as a one-time check when the campaign launches. This is a genuinely moving regulatory target.

What's the biggest risk in compounded GLP-1 marketing right now?

Continuing to run shortage-era marketing claims after the underlying shortage designation or compounding exception has changed, without updating the offer or the compliance basis behind it.